BBIO Stock Overview
A commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BridgeBio Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.54 |
| 52 Week High | US$44.32 |
| 52 Week Low | US$21.62 |
| Beta | 1.09 |
| 11 Month Change | -13.37% |
| 3 Month Change | -11.82% |
| 1 Year Change | -20.38% |
| 33 Year Change | -44.94% |
| 5 Year Change | -20.33% |
| Change since IPO | -18.19% |
Recent News & Updates
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analysts Are More Bearish Than They Used To Be
Nov 19
Revenues Not Telling The Story For BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Sep 24Recent updates
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analysts Are More Bearish Than They Used To Be
Nov 19Revenues Not Telling The Story For BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Sep 24BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis
Aug 31BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On Horizon
Aug 17BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing
Jun 10BridgeBio Pharma: Upping An Existing Position (Rating Upgrade)
Jun 03BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck
Jan 11Estimating The Intrinsic Value Of BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Nov 06BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing
Jul 02New Forecasts: Here's What Analysts Think The Future Holds For BridgeBio Pharma, Inc. (NASDAQ:BBIO)
May 09Time To Worry? Analysts Just Downgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Outlook
Feb 28Analysts Just Made A Major Revision To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Revenue Forecasts
Jan 09BridgeBio stock rises as BBP-398, Lumakras combo for lung cancer gets FDA fast track status
Oct 11BridgeBio, Sentynl's Nulibry for rare disorder in children gets approval in EU
Sep 20Shareholder Returns
| BBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.4% | -10.5% | -2.1% |
| 1Y | -20.4% | 12.7% | 29.7% |
Return vs Industry: BBIO underperformed the US Biotechs industry which returned 12.7% over the past year.
Return vs Market: BBIO underperformed the US Market which returned 29.7% over the past year.
Price Volatility
| BBIO volatility | |
|---|---|
| BBIO Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BBIO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BBIO's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 553 | Neil Kumar | bridgebio.com |
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
BridgeBio Pharma, Inc. Fundamentals Summary
| BBIO fundamental statistics | |
|---|---|
| Market cap | US$4.22b |
| Earnings (TTM) | -US$438.86m |
| Revenue (TTM) | US$217.77m |
19.6x
P/S Ratio-9.7x
P/E RatioIs BBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BBIO income statement (TTM) | |
|---|---|
| Revenue | US$217.77m |
| Cost of Revenue | US$2.39m |
| Gross Profit | US$215.37m |
| Other Expenses | US$654.23m |
| Earnings | -US$438.86m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.32 |
| Gross Margin | 98.90% |
| Net Profit Margin | -201.53% |
| Debt/Equity Ratio | -141.1% |
How did BBIO perform over the long term?
See historical performance and comparison